CEO Richard Batycky said the capital would be used to bring Nocion’s lead drug into a Phase 2b study in chronic cough patients and to prepare for a Phase 3 trial. But just last year, Batycky said the future of Nocion wasn’t so certain.
Source link
Biotech Nocion was in 'a real pickle,' then raised $62M in venture capital
